1. Home
  2. VZLA vs MNMD Comparison

VZLA vs MNMD Comparison

Compare VZLA & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VZLA

Vizsla Silver Corp.

HOLD

Current Price

$5.19

Market Cap

1.6B

Sector

N/A

ML Signal

HOLD

Logo Mind Medicine (MindMed) Inc.

MNMD

Mind Medicine (MindMed) Inc.

HOLD

Current Price

$12.61

Market Cap

960.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VZLA
MNMD
Founded
2017
2019
Country
Canada
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
960.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
VZLA
MNMD
Price
$5.19
$12.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
9
Target Price
$7.00
$25.78
AVG Volume (30 Days)
8.8M
1.5M
Earning Date
12-09-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.67
$4.70
52 Week High
$5.61
$14.43

Technical Indicators

Market Signals
Indicator
VZLA
MNMD
Relative Strength Index (RSI) 62.72 55.67
Support Level $5.00 $12.19
Resistance Level $5.12 $13.45
Average True Range (ATR) 0.27 0.70
MACD 0.04 0.08
Stochastic Oscillator 73.46 72.07

Price Performance

Historical Comparison
VZLA
MNMD

About VZLA Vizsla Silver Corp.

Vizsla Silver Corp is a junior mineral exploration and development company focused on advancing its Panuco silver-gold project located in Sinaloa, Mexico. The property contains quartz-carbonate veins with workings defining both steeply plunging and sub-horizontal ore shoots. Mineralization occurs as silver sulphides including argentite and acanthite, native gold, electrum and native silver associated with pyrite, minor galena, sphalerite and rare chalcopyrite. It has one operating segment, which is principally mineral exploration.

About MNMD Mind Medicine (MindMed) Inc.

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Share on Social Networks: